February 26, 2018 / 12:13 PM / 7 months ago

BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial

Feb 26 (Reuters) - Axsome Therapeutics Inc:

* AXSOME THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 1 TRIAL OF NEXT GENERATION PRODUCT CANDIDATE AXS-09 CONTAINING CHIRALLY PURE ESBUPROPION AND DEXTROMETHORPHAN

* AXSOME THERAPEUTICS INC - ‍CHIRALLY PURE AND STABLE SINGLE ENANTIOMERS OF BUPROPION ACHIEVED​

* AXSOME THERAPEUTICS INC - ‍AXS-09 WAS WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED IN TRIAL​

* AXSOME THERAPEUTICS INC - ‍ AXS-09 RESULTS IN SUBSTANTIAL INCREASES IN DEXTROMETHORPHAN PLASMA LEVELS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below